Biopharmaceuticals - Specialty/Rare Disease and Generics
Strategic Profile
ANI is accelerating its transformation into a leading Rare Disease company in 2026, supported by strong execution in Generics and disciplined capital deployment. Cortrophin Gel, the company's lead rare disease asset, delivered 2025 net revenues of $347.8 million, up 76% year-over-year, with rare disease projected to represent approximately 60% of total 2026 net revenues.
Cyborg Score Rationale
ANI posted strong Q4 earnings with rare disease revenue surging 50% and a swing to net income of $27.5 million compared to prior year losses. The company is generating >$1B in revenue with >60% contribution from high-growth rare disease. However, payer pushback on high-cost rare disease drugs could quickly change the risk profile.
Top Insights
Q4 2025 adjusted earnings beat consensus ($2.33 vs $2.00) with Rare Disease segment growing 50.8%.
2026 guidance targets $1.055-$1.115B revenue (vs consensus $982.5M) with Cortrophin Gel revenue guidance of $540-$575M and adjusted EPS of $8.83-$9.34.
The company has a commercial portfolio of approximately 118 products.
Insider activity shows 17 stock sales and zero purchases in the past 6 months, indicating potential confidence concerns.
Named Competitors
Specialty pharma/rare disease rivals — Focus on ophthalmology, rheumatology, and specialty indications
Generic pharmaceutical manufacturers — Compete in U.S. generics markets with R&D and manufacturing scale
Recent Developments
(February 2026) Reported record full-year 2025 revenues of $883.4M (+43.8% YoY) and reaffirmed 2026 guidance of $1.06-$1.12B
(February 2026) Announced CEO and executive team presentations at Raymond James, Leerink Partners, and Barclays healthcare conferences in March 2026
(January 2026) Provided 2026 financial guidance projecting Cortrophin Gel revenue of $540-$575M and rare disease representing 60% of total revenues
Open the full interactive ANI Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.